1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 8th April 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

TFEB induces mitochondrial itaconate synthesis to suppress bacterial growth in macrophages, 2022, Schuster et al

Discussion in ''Conditions related to ME/CFS' news and research' started by darrellpf, Jul 22, 2022.

  1. darrellpf

    darrellpf Established Member (Voting Rights)

    Messages:
    54
    "Successful elimination of bacteria in phagocytes occurs in the phago-lysosomal system, but also depends on mitochondrial pathways. Yet, how these two organelle systems communicate is largely unknown. Here we identify the lysosomal biogenesis factor transcription factor EB (TFEB) as regulator for phago-lysosome-mitochondria crosstalk in macrophages. By combining cellular imaging and metabolic profiling, we find that TFEB activation, in response to bacterial stimuli, promotes the transcription of aconitate decarboxylase (Acod1, Irg1) and synthesis of its product itaconate, a mitochondrial metabolite with antimicrobial activity. Activation of the TFEB–Irg1–itaconate signalling axis reduces the survival of the intravacuolar pathogen Salmonella enterica serovar Typhimurium. TFEB-driven itaconate is subsequently transferred via the Irg1-Rab32–BLOC3 system into the Salmonella-containing vacuole, thereby exposing the pathogen to elevated itaconate levels. By activating itaconate production, TFEB selectively restricts proliferating Salmonella, a bacterial subpopulation that normally escapes macrophage control, which contrasts TFEB’s role in autophagy-mediated pathogen degradation. Together, our data define a TFEB-driven metabolic pathway between phago-lysosomes and mitochondria that restrains Salmonella Typhimurium burden in macrophages in vitro and in vivo."

    https://www.nature.com/articles/s42255-022-00605-w
     
    Lisa108, Hutan and alktipping like this.
  2. Hutan

    Hutan Moderator Staff Member

    Messages:
    26,850
    Location:
    Aotearoa New Zealand
    Interesting paper, confirming the itaconate shunt as a means of controlling bacteria in macrophages and demonstrating that measuring levels of itaconate in cells is straight-forward.

     
  3. Hutan

    Hutan Moderator Staff Member

    Messages:
    26,850
    Location:
    Aotearoa New Zealand
    Itaconate produced by mitochondria can be moved into vacuoles containing pathogen bacteria where it inhibits pathogen proliferation.
    Most of the authors of this article are based in Freiburg, Germany.

    I thought the mention of iNOS as an inhibitor of itaconate synthesis was interesting, given its possible link to brain and CNS pathologies.
     
    alktipping, SNT Gatchaman and Lisa108 like this.
  4. Hutan

    Hutan Moderator Staff Member

    Messages:
    26,850
    Location:
    Aotearoa New Zealand
    Here's an explanation of how TFEB becomes activated (TFEBa) so it can then potentially go on to turn on the itaconate shunt):
    (Basically, the TFEB molecule sits in the cytosol, inactive. Then, when there is some adverse condition e.g. starvation , infection, ROS, ER stress or mitochondrial damage, it is dephosphoyrlated and moves to the nucleus, becoming active. mTOR, ERK2 and PKC are involved in TFEB becoming active.

    Emerging role of transcription factor EB in mitochondrial quality control 2020
    So, there are potentially quite a number of problems that could result in TFEB becoming active, although I'm not sure if they all result in TFEB turning on the itaconate shunt. (The paper that is the subject of this thread reported their finding that
    " TFEB activation alone is sufficient to produce itaconate without additional need for a pro-inflammatory macrophage signal.")
     
    Last edited: Jul 23, 2022
    alktipping, Lisa108 and Trish like this.

Share This Page